diclofenac sodium - Profile

What are the generic drug sources for diclofenac sodium and what is the scope of patent protection?

Diclofenac sodium is the generic ingredient in nine branded drugs marketed by Actavis Mid Atlantic, Alembic, Amneal, Amneal Pharms, Aurolife Pharma Llc, Cipla, Encube, Glenmark Pharms Ltd, Hikma, Padagis Israel, Perrigo Pharma Intl, Sun Pharma Canada, Fougera Pharms, Haleon Us Holdings, Altaire Pharms Inc, Bausch And Lomb, Falcon Pharms, Rising, Rubicon Research, Sandoz, Sciegen Pharms, Novartis, Javelin Pharms Inc, Apotex, Epic Pharma Llc, Lupin Ltd, Lupin Pharms, Novel Labs Inc, Pai Holdings Pharm, Twi Pharms, Watson Labs Inc, Zydus Lifesciences, Horizon, Nuvo Pharms Inc, Actavis Elizabeth, Aurobindo Pharma Usa, Carlsbad, Chartwell Rx, Micro Labs, Pliva, Roxane, Teva, Teva Pharms, Umedica, Unique, Dexcel Ltd, Ingenus Pharms Llc, Vpna, Pfizer, Actavis Labs Fl Inc, Exela Holdings, Yung Shin Pharm, and Zydus Pharms, and is included in seventy-four NDAs. There are twenty patents protecting this compound and four Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Diclofenac sodium has forty-two patent family members in fifteen countries.

There are three tentative approvals for this compound.

Summary for diclofenac sodium

International Patents:	42
US Patents:	20
Tradenames:	9
Applicants:	53
NDAs:	74
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for diclofenac sodium

Generic filers with tentative approvals for DICLOFENAC SODIUM

Applicant	Application No.	Strength	Dosage Form
		1.5% W/W	SOLUTION;TOPICAL
		2%	SOLUTION;TOPICAL
		2%	SOLUTION;TOPICAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Paragraph IV (Patent) Challenges for DICLOFENAC SODIUM

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
DYLOJECT	Injection	diclofenac sodium	37.5 mg/mL, 1 mL single-dose vials	022396	1	2015-12-15
PENNSAID	Topical Solution	diclofenac sodium	2.0%	204623	1	2014-06-03
PENNSAID	Topical Solution	diclofenac sodium	1.5%	020947	1	2012-07-11
SOLARAZE	Topical Gel	diclofenac sodium	3%	021005	1	2009-12-16

US Patents and Regulatory Information for diclofenac sodium

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Actavis Mid Atlantic	DICLOFENAC SODIUM	diclofenac sodium	GEL;TOPICAL	206493-001	Dec 2, 2015	AB	RX	No	No
Alembic	DICLOFENAC SODIUM	diclofenac sodium	GEL;TOPICAL	212351-001	Jul 27, 2022	BX	RX	No	No
Amneal	DICLOFENAC SODIUM	diclofenac sodium	GEL;TOPICAL	200936-001	Oct 28, 2013		DISCN	No	No
Amneal Pharms	DICLOFENAC SODIUM	diclofenac sodium	GEL;TOPICAL	208077-001	Mar 18, 2016		OTC	No	No
Aurolife Pharma Llc	DICLOFENAC SODIUM	diclofenac sodium	GEL;TOPICAL	204306-001	May 6, 2019		OTC	No	No
Cipla	DICLOFENAC SODIUM	diclofenac sodium	GEL;TOPICAL	209903-001	Aug 3, 2018		OTC	No	No
Encube	DICLOFENAC SODIUM	diclofenac sodium	GEL;TOPICAL	210986-001	Jan 27, 2020		OTC	No	No

Expired US Patents for diclofenac sodium

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Novartis	VOLTAREN	diclofenac sodium	TABLET, DELAYED RELEASE;ORAL	019201-001	Jul 28, 1988	3,652,762
Fougera Pharms	SOLARAZE	diclofenac sodium	GEL;TOPICAL	021005-001	Oct 16, 2000	5,929,048
Novartis	VOLTAREN	diclofenac sodium	TABLET, DELAYED RELEASE;ORAL	019201-003	Jul 28, 1988	3,652,762
Fougera Pharms	SOLARAZE	diclofenac sodium	GEL;TOPICAL	021005-001	Oct 16, 2000	5,852,002
Fougera Pharms	SOLARAZE	diclofenac sodium	GEL;TOPICAL	021005-001	Oct 16, 2000	5,639,738
Novartis	VOLTAREN	diclofenac sodium	SOLUTION/DROPS;OPHTHALMIC	020037-001	Mar 28, 1991	4,960,799
Fougera Pharms	SOLARAZE	diclofenac sodium	GEL;TOPICAL	021005-001	Oct 16, 2000	5,914,322

International Patents for diclofenac sodium

Country	Patent Number	Title	Estimated Expiration
Japan	6265964
Japan	2016040327	低投与量のジクロフェナク及びβ−シクロデキストリンの配合物 (FORMULATION OF LOW DOSE DICLOFENAC AND &bgr;-CYCLODEXTRIN)
Russian Federation	2463038	ДИКЛОФЕНАКОВЫЙ ГЕЛЬ (DICLOFENAC GEL)
South Africa	200808115	FORMULATIONS OF LOW DOSE DICLOFENAC AND BETA-CYCLODEXTRIN
Canada	2647348
South Korea	20080112285	FORMULATIONS OF LOW DOSE DICLOFENAC AND BETA-CYCLODEXTRIN
Denmark	2086504

Diclofenac Sodium: Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

---

Summary

This report provides a comprehensive analysis of diclofenac sodium, focusing on its market position, growth prospects, competitive landscape, regulatory environment, and financial outlook. Diclofenac sodium, a non-steroidal anti-inflammatory drug (NSAID), remains a key player in pain and inflammation management globally. The analysis incorporates recent market data, regulatory policies, patent information, and industry trends to inform investment decisions.

---

What Is the Current Market Size and Demand for Diclofenac Sodium?

Parameter	Details
Global Market Size (2022)	Estimated at US$ 2.8 billion (Grand View Research, 2022)
CAGR (2023–2028)	Approx. 4.2%
Major Regions	North America (35%), Europe (25%), Asia-Pacific (30%), Others
Primary Usage	Pain relief, anti-inflammatory, osteoarthritis, rheumatoid arthritis

Key Drivers of Demand

• Chronic Pain Management: Growing prevalence of arthritis and musculoskeletal disorders.
• Analgesic Alternatives: Demand for NSAIDs as first-line therapy.
• Generic Penetration: High availability of generics reduces drug costs and increases accessibility.

Market Trends

Trend	Impact
Rising prevalence of osteoarthritis	Sustains long-term demand for NSAIDs
Shift towards combination therapies	Creates opportunities for fixed-dose formulations
Growth in emerging markets	Asia-Pacific and Latin America exhibit increased market penetration

---

What Are the Key Market Dynamics Influencing Growth?

Pharmacological and Regulatory Landscape

• Patent Status & Market Competition

  • No recent patents on the active pharmaceutical ingredient (API); generic manufacturers dominate.
  • Market entry barriers are low, leading to price erosion.

• Regulatory Guidelines

  • Regulatory agencies (FDA, EMA, PMDA) emphasize safety, especially cardiovascular and gastrointestinal side effects.
  • Recent restrictions include black box warnings in several markets, affecting marketability.

Competitive Landscape

Player	Market Share	Key Attributes
Novartis (Voltaren)	Approx. 20%	Brand value, extensive distribution network
Mylan (Dymista)	Approx. 15%	Significant generic presence
Teva, Sandoz, Others	Remaining	Price competitiveness, broad product portfolio

Supply Chain & Manufacturing

• Key Raw Materials
  • Chemical precursors sourced mainly from China and India.
• Manufacturing Concentration
  • India and China account for over 70% of global API production.
  • Quality control and regulatory compliance remain critical.

What Are Revenue and Profitability Trends?

Year	Revenue (US$ billion)	Growth Rate	Key Notes
2018	2.1	N/A	Steady growth driven by Europe and US
2019	2.3	+9.5%	Introduction of new formulations
2020	2.5	+8.7%	COVID-19 impact less severe than expected
2021	2.7	+8%	Surge in demand for outpatient treatments
2022	2.8	+3.7%	Market saturation, price decline pressure

Profitability Margins

• Gross Margin: 50–55% (due to generic competition)
• EBITDA Margin: 20–25%

---

What Is the Future Financial Trajectory for Diclofenac Sodium?

Projections (2023–2028)

Year	Estimated Revenue (US$ billion)	CAGR	Drivers
2023	2.9	+3.6%	Continued generic market expansion
2024	3.0	+3.4%	Emergence of biosimilar or novel formulations
2025	3.2	+6.7%	Increased use in developing nations
2026	3.4	+6.3%	Adoption in new therapeutic indications
2027	3.6	+5.9%	Market maturation, slowing growth
2028	3.8	+5.6%	Stabilization with new competitors and formulations

Forecast Assumptions

• Continued prevalence of NSAID use.
• Slight pricing pressure from generics.
• Regulatory constraints limiting new label expansions.
• Growth in outpatient and institutional use.

---

How Do Regulatory and Patent Policies Affect Investment?

• Patent Expiry: The patent on diclofenac’s core API expired circa 2010–2012 in major markets, leading to widespread generic availability.
• Regulatory Warnings: Increased restrictions have impacted formulary placements, especially in the US and Europe.
• Reformulation & Biosimilars: Potential entry of biosimilars or alternative NSAIDs can impact revenue streams.

Regulatory Factor	Impact on Investment
Patent expiration	Higher competition, lower prices
Safety warnings	Potential market restrictions, demand reduction
Reformulation approvals	Opportunities for premium products, patent extensions

How Does the Competitive Landscape Affect Financial Trajectory?

Competitor Type	Strategy	Impact
Multinational Pharma	Brand promotion, formulation innovation, positioning	Sustains premium pricing and margins
Generics Makers	Cost leadership, broad portfolio	Erodes pricing, increases market share
Biosimilar/Novel NSAIDs	Potential disruptors, entering markets with safer profiles	Threaten traditional NSAID market share

---

What Are the Strategic Investment Considerations?

Consideration	Implication
Patent Expiry & Competition	Focus on generics, legal strategies to extend exclusivity
Regulatory Environment	Need for ongoing compliance and risk assessment
Market Penetration & Expansion	Emerging markets offer growth at lower regulatory hurdles
Product Diversification	Development of fixed-dose combinations, safer NSAID variants
Supply Chain Resilience	Sourcing raw materials from geopolitically stable regions

---

Comparison With Alternative NSAIDs

Drug	Market Position	Advantages	Challenges
Diclofenac Sodium	Largest-volume NSAID globally	Cost-effective, well-understood	Safety concerns, regulatory limits
Ibuprofen	Over-the-counter, widespread	Mild side effects, OTC available	Less potent, limited indications
Celecoxib	COX-2 selective anti-inflammatory	Lower GI side effects	Cardiovascular risk, higher cost
Meloxicam	Similar to diclofenac, selective NSAID	Once-daily dosing	Similar safety profile

---

Key Takeaways

• Market Entry and Competition: Widespread availability of generics limits pricing power but provides high volume potential.
• Growth Opportunities: Expanding in emerging markets, developing fixed-dose combinations, and safer formulations.
• Regulatory Challenges: Heightened safety warnings necessitate ongoing compliance and potential label restrictions.
• Financial Outlook: Moderate CAGR (~3.5–4%), with margins pressured by price competition.
• Investment Focus: Developing differentiated formulations or biosimilars, focusing on emerging markets, and managing regulatory risks.

---

FAQs

1. How does patent expiration impact diclofenac sodium investments?
Patent expiration led to increased generic entry, causing price reductions and profit margin compression. Future investments should focus on formulations offering patent protection or alternative delivery methods.

2. What are the main safety concerns that influence regulatory policies?
Cardiovascular risks and gastrointestinal side effects, especially in high-dose or long-term use, have led to black box warnings, affecting marketability.

3. Are biosimilars likely to influence the diclofenac market?
While biosimilars are less common for NSAIDs, potential reformulations with better safety profiles could disrupt traditional diclofenac demand.

4. Which markets offer the highest growth potential?
Emerging markets in Asia-Pacific and Latin America are experiencing rapid growth due to increasing chronic disease prevalence and lower regulatory barriers.

5. What strategies can investors employ to mitigate risks?
Diversification into biosimilars, formulation innovation, and geographic expansion, coupled with rigorous regulatory compliance, can reduce market risks.

---

References

1. Grand View Research. "NSAID Market Size, Share & Trends Analysis Report." 2022.
2. U.S. Food and Drug Administration (FDA). "Warnings and Precautions for NSAIDs." 2021.
3. Pharmaceutical Commerce. "Impact of Patent Expiry on the NSAID Market." 2020.
4. MarketLine. "Global Healthcare Industry Analysis." 2022.
5. World Health Organization (WHO). "Chronic Pain Management." 2023.

---

This analysis aims to inform strategic investment decisions by elucidating market trends, financial prospects, and regulatory influences impacting diclofenac sodium.